Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03801200
Recruitment Status : Not yet recruiting
First Posted : January 11, 2019
Last Update Posted : May 21, 2019
Sponsor:
Information provided by (Responsible Party):
HAN GUANG, Hubei Cancer Hospital

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of concurrent radiotherapy with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung Cancer (NSCLC).

Condition or disease Intervention/treatment Phase
NSCLC Drug: Apatinib Phase 2

Detailed Description:

Brain metastases (BM) develop in 22-54% of NSCLC patients during the disease course. NSCLC patients with BM with a median overall survival (OS) of 2-3 months when treated with systemic corticosteroid alone, and a median OS of 3-6 months when treated with whole brain radiation therapy (WBRT). Recently, several studies have reported the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for EGFR mutation NSCLC patients with BM. The median OS of EGFR mutation patients with BM significantly improved with TKIs treatment, which ranged from 11.8 to 18.8 months. However, for the EGFR wide-type NSCLC patients with BM, the prognosis remains poor.

It was found that the combination of anti-VEGF drugs and brain radiotherapy can not only reduce the volume of peritumoral brain edema (PTBE), reduce the intracranial pressure, relieve the symptoms of nerve compression, reduce the risk of brain hernia during brain radiotherapy, and but also inhibit the hypoxia of tumor cells, increase the radiosensitivity of tumor cells, and ultimately improve the efficacy of radiotherapy.

Apatinib, a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor (VEGFR) and mildly inhibits c-Kit and c-SRC, has been reported to show efficacy among some patients with malignant supratentorial gliomas.

Therefore, the investigators initiated this study to evaluate the efficacy and safety of concurrent radiotherapy with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung Cancer (NSCLC).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomized Controlled Trial of Apatinib Combined With Radiotherapy in Patient With Brain Metastases From Drive Gene Negative NSCLC
Estimated Study Start Date : July 1, 2019
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : July 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Apatinib combined with Radiotherapy

Drugs: Apatinib Apatinib (500 mg/d) was given orally for one week before the brain radiotherapy, and then, continued to be administered at the same way during the brain radiotherapy period (3 weeks). It was given for another one week after the end of the brain radiotherapy.

Radiotherapy: Intensity-modulated radiotherapy (IMRT).

According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:

  1. 37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;
  2. The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy/15 to patients with 1-5 metastatic lesions.
Drug: Apatinib
radiotherapy with Apatinib
Other Name: Apatinib Mesylate

No Intervention: Radiotherapy alone

Radiotherapy: Intensity-modulated radiotherapy (IMRT).

According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:

  1. 37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;
  2. The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy /15 to patients with 1-5 metastatic lesions.



Primary Outcome Measures :
  1. Intracranial progression-free survival (iPFS) [ Time Frame: Evaluated in 24 months since the treatment began ]
    Defined as the time from randomisation to progression of intracranial disease or death from any cause.

  2. Objective response rate (ORR) [ Time Frame: 4 weeks after Radiotherapy. ]
    Proportion of patients with reduction in tumor burden of a predefined amount

  3. Disease control rate (DCR) [ Time Frame: 4 weeks after Radiotherapy. ]
    Proportion of patients with reduction or keeping in stable in tumor burden of a predefined amount


Secondary Outcome Measures :
  1. intracranial time to progress (ITTP) [ Time Frame: Tumor assesment at 4 weeks and 12 weeks after radiotherapy, and then every 12 weeks, up to 24 months ]
    Defined as the time from randomisation to progression of intracranial disease

  2. Overall survival (OS) [ Time Frame: Tumor assesment at 4 weeks and 12 weeks after radiotherapy, and then every 12 weeks, up to 24 months ]
    Defined as the time from randomisation to death from any cause

  3. Rate of Peritumoalbrainedema (PTBE) [ Time Frame: 4 weeks after Radiotherapy. ]
    PTBE volume was measured in a similar manner by measuring the high SI region in T2WI that was clearly distinguished from normal tissues, including the tumor. Edema index was calculated by dividing the PTBE volume by tumor volume. The Edema index represents the degree of the PTBE, compared to tumor volume, with an index of 1.0 indicating no PTBE development.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-75 years old, male or female, signed informed consent;
  2. The primary lesion is confirmed by histopathology. The patient with brain metastases confirmed by histopathology or imaging confirmed the brain metastases. All patients with non-small cell lung cancer brain metastases should be recommended for EGFR mutation and ALK gene rearrangement assay,exclusion of patients with NSCLC brain metastases with positive EGFR-sensitive mutations and ALK gene rearrangement detection for TKI treatment; After multidisciplinary consultation and evaluation, patients with single or local multiple metastatic tumors with well-controlled primary lesions, who have the economic ability and are willing to undergo surgery for brain metastatic tumors were excluded.
  3. Observable imaging data such as CT, MRI, etc., have measurable lesions as defined by RECIST 1.1 (R09-0262);
  4. ECOG PS score: 0-2;
  5. Hemogram index: RBC≥3.0×1012/L, WBC≥3.5×109/L, ANC≥1.5×109/L, PLT≥100×109/L, Hb≥90g/L
  6. the expected survival time ≥ 3 months
  7. Renal function: Cr≤1.2×UNL (upper limit of normal value);
  8. Liver function: total bilirubin ≤ 1.5 × UNL; ALT, AST ≤ 1.5 × UNL

Exclusion Criteria:

  1. . Allergies, known to be hypersensitive to any excipients in the study drug. ;
  2. . Patients with recurrent brain metastases have previously received brain radiation therapy
  3. . Patients with high fever and acute infection;
  4. . Patients with active, progressive bleeding or a significant bleeding tendency in the primary lesion;
  5. . Participated in any clinical trial of research drugs within 4 weeks prior to enrollment
  6. . Diarrhea is the main symptom of the important or newly diagnosed acute gastrointestinal diseases, such as Crohn's disease, malabsorption or any cause of CTC ≥ 2 grade diarrhea.
  7. . Current clinically relevant cardiovascular disease or medical history, such as refractory hypertension, NYHA grade 3 congestive heart failure, unstable angina or poorly controlled arrhythmias. Myocardial infarction occurred 6 months before randomization.
  8. . Absolute neutrophil count <1000/mm3;
  9. . Platelet count <50000/mm3;
  10. . According to the investigator's point of view, any other serious disease or organ system dysfunction that may affect patient safety or interfere with the safety assessment of the test drug, such as proteinuria (CTCAE4.0-≥3), severe liver and kidney dysfunction (CTCAE4.0-≥3), hand-foot syndrome (CTCAE4.0-≥3) and so on.
  11. . There are ulcers, intestinal perforations, and intestinal obstruction.
  12. . Pregnant and lactating women
  13. . Suspected or indeed have a history of alcohol and drug abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03801200


Contacts
Layout table for location contacts
Contact: Guang Han, M.D.; PH.D 13886048178 hg7913@hotmail.com

Locations
Layout table for location information
China, Hubei
Hubei Cancer hospital Recruiting
Wuhan, Hubei, China, 430079
Contact: Han Guang, MD.; PH.D         
Sponsors and Collaborators
Hubei Cancer Hospital
Investigators
Layout table for investigator information
Study Director: Desheng Hu Associate dean

Layout table for additonal information
Responsible Party: HAN GUANG, Professor of Medicine, Hubei Cancer Hospital
ClinicalTrials.gov Identifier: NCT03801200     History of Changes
Other Study ID Numbers: HBCH RT-2019-01
First Posted: January 11, 2019    Key Record Dates
Last Update Posted: May 21, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by HAN GUANG, Hubei Cancer Hospital:
Brain metastasis
Apatinib
Radiotherapy
NSCLC
Drive gene negative
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Apatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action